- Lewis Chodosh, University of Pennsylvania
miRNA expression profiles of distinct epithelial subpopulations shed light on the role of miRNA and the epigenome in mammary cell differentiation and oncogenesis.
Heightened anti-HER2 CD4+Th1 immune responses correlate with pathologic complete response following breast cancer treatment, suggesting that immune interventions may complement standard strategies for treating HER2+ breast cancer.
Nanoparticles which combine magnetic hyperthermia and anti-cancer drug delivery show potential as a new treatment to target and kill breast cancer cells.
Carol Fabian et al. review early investigations into the use of omega-3 supplementation to prevent breast cancer and to improve outcomes following breast cancer diagnosis.
Adipose cells in the tumour microenvironment may be contributing to resistance to Trastuzumab, a targeted treatment for HER2+ breast cancer.
Long non-coding RNA profiles were found to predict risk of metastases in lymph node-negative breast cancer patients, and hence may be a source of prognostic information used to combat overtreatment.
From the blog
Aims & scope
Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, editorials and reports. Open access research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal publishes preclinical, translational and clinical studies with a biological basis, including Phase I and Phase II trials.